IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic pharmaceutical company, announced today that the Company will partner with DDN, a Dohmen Company, the largest privately-held provider of outsourced business services to the life science industry.
IGI will launch its first IGI labeled generic products later this year. DDN will provide product launch support, logistics support and order to cash services.
Jason Grenfell-Gardner, President and Chief Executive Officer (CEO) of IGI, said, “Our partnership with DDN completes a significant step in our go to market strategy, and we are extremely pleased to have DDN as a partner to help guide us through the logistics regarding the launch of our first IGI labeled products later this year. As I have mentioned, there were several steps in the execution of our go to market strategy, and now with DDN in place, IGI can focus on aggressively selling and marketing our IGI label products.”
DDN President Mark Wiesman, said, “We look forward to providing support to IGI as they launch their products into the marketplace. Our goal is to provide broad expertise and scalable infrastructure to life science companies such as IGI, allowing them to focus their attention and capital on rapidly growing their business. We look forward to partnering with IGI as together we provide outstanding service to their customers.”About IGI Laboratories, Inc. IGI Laboratories is a developer and manufacturer of topical formulations for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be a leading player in the generic topical prescription drug market. About DDN DDN, a Dohmen company, provides conflict-free business support services to global emerging, mid-tier and large life science companies. DDN is uniquely aligned with manufacturers to create efficiencies, reduce cost and solve complex business challenges within the healthcare supply system. Visit www.ddnnet.com. IGI Laboratories, Inc. “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as " will," "possible," "one time," "provides an opportunity," "continue" or words of similar meaning. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in IGI Laboratories, Inc.’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Actual results may differ materially from these expectations due to changes in global political, economic, business, competitive, market and regulatory factors or IGI Laboratories, Inc.’s ability to implement business strategies. IGI Laboratories, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV